Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma (Epitopes-HPV02)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02402842|
Recruitment Status : Active, not recruiting
First Posted : March 30, 2015
Last Update Posted : October 6, 2017
Squamous cell carcinoma of the anal canal (SCCA) is a rare disease and mostly diagnosed at an early stage. After standard concurrent chemoradiation (CRT) with mitomycin (MMC) and 5-fluorouracil (5FU), the disease will recur in 20% of patients. After treatment failure (including salvage surgery), cisplatin-5FU combination is the standard option but complete response is a rare event and the prognosis remains poor with most patients' death occurring in the first 12 months. Decision making for physicians in this setting is only based on retrospective studies or small phase II clinical trials including less than 20 patients. Hence, no efficient standard of care is currently available for relapsing SCCA patients who are currently treated with a palliative intent.
Between 2007 and 2013, 8 consecutive patients with advanced recurrent SCCA after CRT were treated with DCF regimen (docetaxel, cisplatin and 5-fluorouracil) in the Regional Cancer Institute of Franche Comté. After a median follow-up of 41 months, 4 patients (50%) achieved a complete response. Three patients underwent surgery of all involved metastatic sites. A pathological complete response was observed for all of them including in metastases occurring in irradiated fields, suggesting that taxane-based chemotherapy might be an effective strategy to circumvent resistance to radiotherapy (a preliminary cohort of 8 patients was published (Kim S et al Annals of oncology 2013). Furthermore, all complete responders were HPV 16, and high levels of specific T cell responses against Human Papillomavirus (HPV) HPV16-derived E6/E7 and telomerase were detected in 50% of complete responders suggesting the potential restoration of cancer immunosurveillance by this regimen.
Then, the Epitopes-HPV02 multicenter phase II study will aim to confirm the new role of taxane-based chemotherapy in SCCA patients.
|Condition or disease||Intervention/treatment||Phase|
|Anal Canal Carcinoma||Drug: Docetaxel, Cisplatin and 5-Fluorouracil||Phase 2|
Epitopes-HPV02 study is a national multicenter open label phase II trial including 66 patients.
Patients will receive 6 cycles of DCF regimen (docetaxel 75 mg/m2 day, CDDP 75 mg/m2 and 5FU at 750 mg/m2/day for 5 days) every 3 weeks or 8 cycles of modified-DCF regimen (docetaxel 40 mg/m2 day, CDDP 40 mg/m2 day and 5-FU at 1200 mg/m2/day for 2 days) every 2 weeks, according to their clinical status.
CT scan will be planned at baseline, after 3 and after 6 cycles of DCF regimen (or after 4 and 8 cycles of modified-DCF regimen) and then every three months until disease progression or death. A Pet-scan will be performed before and after 6 cycles of DCF. Tumor assessment will be carried out according to RECIST V1.1 criteria.
This study is carried out by the University Hospital of Besançon and were approved by the independent Est-II French Committee for Protection of Persons (CPP) and by the French Health Products Safety Agency (ANSM). This study will be conducted in 17 clinical centers in France.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||70 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Assessment of the Clinical Value of a Docetaxel, Cisplatin and 5-fluorouracil (DCF) Strategy Adapted to Patients for the Management of Metastatic or Locally Advanced Anal Resistant Radiochemotherapy Squamous Cell Anal Carcinoma.|
|Study Start Date :||September 2014|
|Estimated Primary Completion Date :||September 2018|
|Estimated Study Completion Date :||September 2021|
Experimental: DCF regimen
docetaxel 75 mg/m2 day, Cisplatin75 mg/m2 and 5Fluorouracil at 750 mg/m2/day for 5 days
Drug: Docetaxel, Cisplatin and 5-Fluorouracil
Patients will receive 6 cycles of DCF regimen (docetaxel 75 mg/m2 day, cisplatin 75 mg/m2 and 5 Fluorouracil at 750 mg/m2/day for 5 days) every 3 weeks or 8 cycles of modified-DCF regimen (docetaxel 40 mg/m2 day, cisplatin 40 mg/m2 day and 5-Fluorouracil at 1200 mg/m2/day for 2 days) every 2 weeks, according to their clinical status.
- Progression-free survival rate [ Time Frame: 12 months after initiation of chemotherapy DCF. ]Progression-free survival observed = the number of patients alive without progression at 12 months.
- Overall survival [ Time Frame: date of death from any cause (within 3 years after the initiation of the treatment) ]time between the date of initiation of treatment and the date of death from any cause.
- Progression free survival [ Time Frame: date of first progression of the disease (within 3 years after the initiation of the treatment) ]time interval between the date of initiation of treatment and the date of first progression (local, remote [extent of the disease by RECIST v1.1] second cancer) or death from any cause.
- response rate [ Time Frame: 4 weeks after the end of DCF regimen ]response rate will be evaluated using Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 by CT-scan
- Tolerance of the DCF regimen ( Common Terminology Criteria for Adverse Events version 4.03) [ Time Frame: from the initiation of DCF regimen to 4 weeks after the end of DCF regimen ]description of toxicities and adverse events according to Common Terminology Criteria for Adverse Events version 4.03
- quality of life related to health [ Time Frame: from the inclusion to patient death or for maximum 3 years after end of treatment ]EORTC-QLQ-C30 & time to QoL score deterioration
- HPV-specific T cell responses measured by ELISPOT assay before and after DCF treatment [ Time Frame: at baseline (inclusion) and 4 weeks after the end of DCF regimen ]HPV-specific T cell responses measured by ELISPOT assay
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02402842
|University hospital of Besançon|
|Besançon, France, 25000|
|FNLCC center Georges François Leclerc|
|Dijon, France, 21000|
|Oscar Lambret center|
|Lille, France, 59000|
|Jean Mermoz Private Hospital|
|Lyon, France, 69 008|
|Hospital of Belfort-Montbeliard|
|Montbeliard, France, 25200|
|Regional Institute of Cancer|
|Montpellier, France, 34 298|
|Institute of Cancerology of Lorraine|
|Nancy, France, 54 519|
|Antoine Lacassagne Center|
|Nice, France, 06 189|
|Paris Saint-Joseph Hospital Group|
|Paris, France, 75 014|
|Paris, France, 75 248|
|Pitié Salpétrière Hospital|
|Paris, France, 75 651|
|Mutualist Montsouris Institute|
|Paris, France, 75 674|
|European Georges Pompidou Hospital|
|Paris, France, 75 908|
|Paris, France, 75571|
|University Robert Debré Hospital|
|Reims, France, 51 092|
|Paul Strauss Center|
|Strasbourg, France, 67 065|